COVID-19: What Do Rheumatologists Need to Know?
Identifieur interne : 000551 ( Main/Corpus ); précédent : 000550; suivant : 000552COVID-19: What Do Rheumatologists Need to Know?
Auteurs : Gillian E. Fitzgerald ; Sinead Maguire ; Nigil HaroonSource :
- Current rheumatology reports [ 1534-6307 ] ; 2021.
English descriptors
- KwdEn :
- MESH :
- chemical , therapeutic use : Antirheumatic Agents.
- complications : COVID-19, Rheumatic Diseases.
- therapy : COVID-19, Rheumatic Diseases.
- Humans, Rheumatology, Telemedicine.
Abstract
PURPOSE OF REVIEW
Severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) emerged in December 2019, rapidly reaching global pandemic proportions. Coronavirus disease 2019 (COVID-19) has presented unique challenges to the rheumatology community. It is known that many individuals with rheumatic disease are at increased risk of severe disease from other infections, sparking a similar fear for COVID-19. In addition, medications routinely used in rheumatology practice are being trialled as treatments, with the potential for drug shortages for rheumatology patients.
RECENT FINDINGS
Underlying comorbidities and active disease are associated with worse COVID-19 outcomes in patients with rheumatic disease. Tocilizumab and hydroxychloroquine have not proven to be effective treatments in the management of COVID-19. Telehealth has become an essential tool for the rheumatology community to monitor patients during the pandemic. In this article, we summarise the available COVID-19 evidence that is of relevance to the rheumatology community. We discuss the risk of contracting COVID-19 in individuals with rheumatic disease, along with presenting features and clinical outcomes. We provide an overview of the treatments for COVID-19 which have significance for rheumatology. We highlight published recommendations which can guide our management of rheumatic disease populations during this pandemic. Finally, we discuss the challenges in delivering effective care virtually and present methods and tools which could be adapted for use.
DOI: 10.1007/s11926-020-00971-y
PubMed: 33403528
PubMed Central: PMC7785126
Links to Exploration step
pubmed:33403528Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">COVID-19: What Do Rheumatologists Need to Know?</title><author><name sortKey="Fitzgerald, Gillian E" sort="Fitzgerald, Gillian E" uniqKey="Fitzgerald G" first="Gillian E" last="Fitzgerald">Gillian E. Fitzgerald</name><affiliation><nlm:affiliation>Department of Rheumatology, Toronto Western Hospital, Toronto, Ontario, Canada. gifitzge@tcd.ie.</nlm:affiliation></affiliation></author><author><name sortKey="Maguire, Sinead" sort="Maguire, Sinead" uniqKey="Maguire S" first="Sinead" last="Maguire">Sinead Maguire</name><affiliation><nlm:affiliation>Department of Rheumatology, St James' Hospital, Dublin, Ireland.</nlm:affiliation></affiliation></author><author><name sortKey="Haroon, Nigil" sort="Haroon, Nigil" uniqKey="Haroon N" first="Nigil" last="Haroon">Nigil Haroon</name><affiliation><nlm:affiliation>Medicine and Rheumatology, University of Toronto, Toronto, Ontario, Canada.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>University Health Network and Mount Sinai Hospital, Scientist, Krembil Research Institute, Toronto, Ontario, Canada.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2021">2021</date><idno type="RBID">pubmed:33403528</idno><idno type="pmid">33403528</idno><idno type="doi">10.1007/s11926-020-00971-y</idno><idno type="pmc">PMC7785126</idno><idno type="wicri:Area/Main/Corpus">000551</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000551</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">COVID-19: What Do Rheumatologists Need to Know?</title><author><name sortKey="Fitzgerald, Gillian E" sort="Fitzgerald, Gillian E" uniqKey="Fitzgerald G" first="Gillian E" last="Fitzgerald">Gillian E. Fitzgerald</name><affiliation><nlm:affiliation>Department of Rheumatology, Toronto Western Hospital, Toronto, Ontario, Canada. gifitzge@tcd.ie.</nlm:affiliation></affiliation></author><author><name sortKey="Maguire, Sinead" sort="Maguire, Sinead" uniqKey="Maguire S" first="Sinead" last="Maguire">Sinead Maguire</name><affiliation><nlm:affiliation>Department of Rheumatology, St James' Hospital, Dublin, Ireland.</nlm:affiliation></affiliation></author><author><name sortKey="Haroon, Nigil" sort="Haroon, Nigil" uniqKey="Haroon N" first="Nigil" last="Haroon">Nigil Haroon</name><affiliation><nlm:affiliation>Medicine and Rheumatology, University of Toronto, Toronto, Ontario, Canada.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>University Health Network and Mount Sinai Hospital, Scientist, Krembil Research Institute, Toronto, Ontario, Canada.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Current rheumatology reports</title><idno type="eISSN">1534-6307</idno><imprint><date when="2021" type="published">2021</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antirheumatic Agents (therapeutic use)</term><term>COVID-19 (complications)</term><term>COVID-19 (therapy)</term><term>Humans (MeSH)</term><term>Rheumatic Diseases (complications)</term><term>Rheumatic Diseases (therapy)</term><term>Rheumatology (MeSH)</term><term>Telemedicine (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antirheumatic Agents</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>COVID-19</term><term>Rheumatic Diseases</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>COVID-19</term><term>Rheumatic Diseases</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term><term>Rheumatology</term><term>Telemedicine</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>PURPOSE OF REVIEW</b></p><p>Severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) emerged in December 2019, rapidly reaching global pandemic proportions. Coronavirus disease 2019 (COVID-19) has presented unique challenges to the rheumatology community. It is known that many individuals with rheumatic disease are at increased risk of severe disease from other infections, sparking a similar fear for COVID-19. In addition, medications routinely used in rheumatology practice are being trialled as treatments, with the potential for drug shortages for rheumatology patients.</p></div><div type="abstract" xml:lang="en"><p><b>RECENT FINDINGS</b></p><p>Underlying comorbidities and active disease are associated with worse COVID-19 outcomes in patients with rheumatic disease. Tocilizumab and hydroxychloroquine have not proven to be effective treatments in the management of COVID-19. Telehealth has become an essential tool for the rheumatology community to monitor patients during the pandemic. In this article, we summarise the available COVID-19 evidence that is of relevance to the rheumatology community. We discuss the risk of contracting COVID-19 in individuals with rheumatic disease, along with presenting features and clinical outcomes. We provide an overview of the treatments for COVID-19 which have significance for rheumatology. We highlight published recommendations which can guide our management of rheumatic disease populations during this pandemic. Finally, we discuss the challenges in delivering effective care virtually and present methods and tools which could be adapted for use.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33403528</PMID><DateCompleted><Year>2021</Year><Month>01</Month><Day>15</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>06</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1534-6307</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>01</Month><Day>05</Day></PubDate></JournalIssue><Title>Current rheumatology reports</Title><ISOAbbreviation>Curr Rheumatol Rep</ISOAbbreviation></Journal><ArticleTitle>COVID-19: What Do Rheumatologists Need to Know?</ArticleTitle><Pagination><MedlinePgn>5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s11926-020-00971-y</ELocationID><Abstract><AbstractText Label="PURPOSE OF REVIEW">Severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) emerged in December 2019, rapidly reaching global pandemic proportions. Coronavirus disease 2019 (COVID-19) has presented unique challenges to the rheumatology community. It is known that many individuals with rheumatic disease are at increased risk of severe disease from other infections, sparking a similar fear for COVID-19. In addition, medications routinely used in rheumatology practice are being trialled as treatments, with the potential for drug shortages for rheumatology patients.</AbstractText><AbstractText Label="RECENT FINDINGS">Underlying comorbidities and active disease are associated with worse COVID-19 outcomes in patients with rheumatic disease. Tocilizumab and hydroxychloroquine have not proven to be effective treatments in the management of COVID-19. Telehealth has become an essential tool for the rheumatology community to monitor patients during the pandemic. In this article, we summarise the available COVID-19 evidence that is of relevance to the rheumatology community. We discuss the risk of contracting COVID-19 in individuals with rheumatic disease, along with presenting features and clinical outcomes. We provide an overview of the treatments for COVID-19 which have significance for rheumatology. We highlight published recommendations which can guide our management of rheumatic disease populations during this pandemic. Finally, we discuss the challenges in delivering effective care virtually and present methods and tools which could be adapted for use.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fitzgerald</LastName><ForeName>Gillian E</ForeName><Initials>GE</Initials><Identifier Source="ORCID">https://orcid.org/0000-0001-5930-3928</Identifier><AffiliationInfo><Affiliation>Department of Rheumatology, Toronto Western Hospital, Toronto, Ontario, Canada. gifitzge@tcd.ie.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maguire</LastName><ForeName>Sinead</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, St James' Hospital, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haroon</LastName><ForeName>Nigil</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Medicine and Rheumatology, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University Health Network and Mount Sinai Hospital, Scientist, Krembil Research Institute, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>01</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Curr Rheumatol Rep</MedlineTA><NlmUniqueID>100888970</NlmUniqueID><ISSNLinking>1523-3774</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018501">Antirheumatic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D018501" MajorTopicYN="N">Antirheumatic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012216" MajorTopicYN="N">Rheumatic Diseases</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012219" MajorTopicYN="Y">Rheumatology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017216" MajorTopicYN="N">Telemedicine</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">COVID-19</Keyword><Keyword MajorTopicYN="Y">Clinical trials</Keyword><Keyword MajorTopicYN="Y">Outcomes</Keyword><Keyword MajorTopicYN="Y">Prevalence</Keyword><Keyword MajorTopicYN="Y">Tele-medicine</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>11</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>1</Month><Day>6</Day><Hour>5</Hour><Minute>56</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>1</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>1</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33403528</ArticleId><ArticleId IdType="doi">10.1007/s11926-020-00971-y</ArticleId><ArticleId IdType="pii">10.1007/s11926-020-00971-y</ArticleId><ArticleId IdType="pmc">PMC7785126</ArticleId></ArticleIdList><ReferenceList><ReferenceList><Title>Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance</Title><Reference><Citation>Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Fu B, Ustianowski AP, et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford). 2011;50(1):124–31.</Citation></Reference><Reference><Citation>Meroni PL, Zavaglia D, Girmenia C. Vaccinations in adults with rheumatoid arthritis in an era of new disease-modifying anti-rheumatic drugs. Clin Exp Rheumatol. 2018;36(2):317–28.</Citation><ArticleIdList><ArticleId IdType="pubmed">29303710</ArticleId></ArticleIdList></Reference><Reference><Citation>Strand V, Ahadieh S, French J, Geier J, Krishnaswami S, Menon S, et al. Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials. Arthritis Res Ther. 2015;17:362.</Citation></Reference><Reference><Citation>Petri M. Infection in systemic lupus Erythematosus. Rheum Dis Clin N Am. 1998;24(2):423–56.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0889-857X(05)70016-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–62.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30566-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun H, Ning R, Tao Y, Yu C, Deng X, Zhao C, et al. Risk factors for mortality in 244 older adults with COVID-19 in Wuhan, China: a retrospective study. J Am Geriatr Soc. 2020;68(6):E19–e23.</Citation><ArticleIdList><ArticleId IdType="pubmed">32383809</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020;368:m1091.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m1091</ArticleId></ArticleIdList></Reference><Reference><Citation>Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. JAMA. 2020;323(16):1574–81.</Citation></Reference><Reference><Citation>Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30183-5</ArticleId></ArticleIdList></Reference><Reference><Citation>• Favalli EG, Ingegnoli F, Cimaz R, Caporali R. What is the true incidence of COVID-19 in patients with rheumatic diseases? Ann Rheum Dis. 2020. https://doi.org/10.1136/annrheumdis-2020-217615 . Favalli et al. published this article as one of the first studies available on COVID-19 in RMDs, in the early stages of the pandemic. This demonstrated a low incidence of the virus in RMD patients.</Citation></Reference><Reference><Citation>Zen M, Fuzzi E, Astorri D, et al. SARS-CoV-2 infection in patients with autoimmune rheumatic diseases in northeast Italy: A crosssectional study on 916 patients. J Autoimmun. 2020. https://doi.org/10.1016/j.jaut.2020.102502 .</Citation></Reference><Reference><Citation>Michelena X, Borrell H, López-Corbeto M, López-Lasanta M, Moreno E, Pascual-Pastor M, et al. Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs. Semin Arthritis Rheum. 2020;50(4):564–70.</Citation></Reference><Reference><Citation>• Pablos JL, et al. Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases. Ann Rheum Dis. 2020;79(9):1170–3. https://doi.org/10.1136/annrheumdis-2020-217763 . Pablos et al. published this large population study on incidence of COVID-19 in hospitalised patients with RMDs which included details on incidence in patients on DMARDs, which was very similar to that of the reference population.</Citation></Reference><Reference><Citation>•• Zhong J, Shen G, Yang H, Huang A, Chen X, Dong L, et al. COVID-19 in patients with rheumatic disease in Hubei province, China: a multicentre retrospective observational study. Lancet Rheumatol. 2020;2(9):e557–e64. Zhong et al. constructed a mutlicenter retrospective review of patients with RMD in China which suggested RMD might increase susceptibility to COVID-19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(20)30227-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferri C, Giuggioli D, Raimondo V, L'Andolina M, Tavoni A, Cecchetti R, et al. COVID-19 and rheumatic autoimmune systemic diseases: report of a large Italian patients series. Clin Rheumatol. 2020;39(11):3195–204. https://doi.org/10.1007/s10067-020-05334-7 .</Citation></Reference><Reference><Citation>Gianfrancesco MA, Hyrich KL, Gossec L, Strangfeld A, Carmona L, Mateus EF, et al. Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries. Lancet Rheumatol. 2020a;2(5):e250–3. https://doi.org/10.1016/S2665-9913(20)30095-3 .</Citation></Reference><Reference><Citation>Haberman R, Axelrad J, Chen A, Castillo R, Yan D, Izmirly P, et al. Covid-19 in immune-mediated inflammatory diseases — case series from New York. N Engl J Med. 2020;383:85–8.</Citation></Reference><Reference><Citation>Monti S, Balduzzi S, Delvino P, Bellis E, Quadrelli VS, Montecucco C. Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. Ann Rheum Dis. 2020;79(5):667–8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-217424</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng C, Li C, Zhao T, Yue J, Yang F, Yan Y, et al. COVID-19 with rheumatic diseases: a report of 5 cases. Clin Rheumatol. 2020;39(7):2025–9. https://doi.org/10.1007/s10067-020-05160-x .</Citation></Reference><Reference><Citation>D'Silva KM, Serling-Boyd N, Wallwork R, Hsu T, Fu X, Gravallese EM, et al. Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US 'hot spot'. Ann Rheum Dis. 2020;79(9):1156–62. https://doi.org/10.1136/annrheumdis-2020-217888 .</Citation></Reference><Reference><Citation>•• Gianfrancesco M, Hyrich KL, Al-Adely S, Carmona L, Danila MI, Gossec L, et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020b;79(7):859–66. https://doi.org/10.1136/annrheumdis-2020-217871 . Gianfrancesco et al. released these much anticipated results from the Global Rheumatology Alliance demonstrating increased risk of hospitalisation in those with co-morbidities and decreased risk in prior treatment with DMARDs and TNF inhibitors.</Citation></Reference><Reference><Citation>Ye C, Cai S, Shen G, Guan H, Zhou L, Hu Y, et al. Clinical features of rheumatic patients infected with COVID-19 in Wuhan, China. Ann Rheum Dis. 2020;79:1007–13.</Citation></Reference><Reference><Citation>Zhao J, Pang R, Wu J, Guo Y, Yang Y, Zhang L, et al. Clinical characteristics and outcomes of patients with COVID-19 and rheumatic disease in China 'hot spot' versus in US 'hot spot': similarities and differences. Ann Rheum Dis. 2020. https://doi.org/10.1136/annrheumdis-2020-218183 .</Citation></Reference><Reference><Citation>Santos CS, Morales CM, Álvarez ED, Castro C, Robles AL, Sandoval TP. Determinants of COVID-19 disease severity in patients with underlying rheumatic disease. Clin Rheumatol. 2020;39(9):2789–96.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-020-05301-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez-Piedra C, Diaz-Torne C, Manero J, Pego-Reigosa JM, Rúa-Figueroa Í, Gonzalez-Gay MA, et al. Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies. Ann Rheum Dis. 2020;79(7):988–90.</Citation></Reference><Reference><Citation>•• Fredi M, Cavazzana I, Moschetti L, Andreoli L, Franceschini F. COVID-19 in patients with rheumatic diseases in northern Italy: a single-centre observational and case-control study. Lancet Rheumatol. 2020;2(9):e549–e56. Fredi et al. published the experience of Italy in the height of the pandemic and showed presence of underlying co-morbidity and increased age was more associated with adverse COVID-19 outcomes than rheumatic diseases.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(20)30169-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Montero F, Martínez-Barrio J, Serrano-Benavente B, González T, Rivera J, Molina Collada J, et al. Coronavirus disease 2019 (COVID-19) in autoimmune and inflammatory conditions: clinical characteristics of poor outcomes. Rheumatol Int. 2020;40(10):1593–8.</Citation></Reference><Reference><Citation>Hasseli R, Mueller-Ladner U, Schmeiser T, Hoyer BF, Krause A, Lorenz HM, et al. National registry for patients with inflammatory rheumatic diseases (IRD) infected with SARS-CoV-2 in Germany (ReCoVery): a valuable mean to gain rapid and reliable knowledge of the clinical course of SARS-CoV-2 infections in patients with IRD. RMD Open. 2020;6(2):e001332. https://doi.org/10.1136/rmdopen-2020-001332 .</Citation></Reference><Reference><Citation>Mikuls TR, Johnson SR, Fraenkel L, Arasaratnam RJ, Baden LR, Bermas BL, et al. American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 1. Arthritis Rheum. 2020;72(8):1241–51. https://doi.org/10.1002/art.41301 .</Citation></Reference><Reference><Citation>Richez C, Flipo RM, Berenbaum F, Cantagrel A, Claudepierre P, Debiais F, et al. Managing patients with rheumatic diseases during the COVID-19 pandemic: The French Society of Rheumatology answers to most frequently asked questions up to May 2020. Joint Bone Spine. 2020;87(5):431–7. https://doi.org/10.1016/j.jbspin.2020.05.006 .</Citation></Reference><Reference><Citation>Schulze-Koops H, Specker C, Iking-Konert C, Holle J, Moosig F, Krueger K. Preliminary recommendations of the German Society of Rheumatology (DGRh eV) for the management of patients with inflammatory rheumatic diseases during the SARS-CoV-2/COVID-19 pandemic. Ann Rheum Dis. 2020;79(6):840–2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-217628</ArticleId></ArticleIdList></Reference><Reference><Citation>Tam LS, Tanaka Y, Handa R, Chang CC, Cheng YK, Isalm N, et al. Care for patients with rheumatic diseases during COVID-19 pandemic: a position statement from APLAR. Int J Rheum Dis. 2020;23:717–22.</Citation></Reference><Reference><Citation>Landewé RB, Machado PM, Kroon F, Bijlsma HW, Burmester GR, Carmona L, et al. EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2. Ann Rheum Dis. 2020;79(7):851–8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-217877</ArticleId></ArticleIdList></Reference><Reference><Citation>Randomised Evaluation of COVID-19 Therapy. RECOVERY Trial. 2020 [cited 2020 30/06/2020]; Available from: https://www.recoverytrial.net/ . Accessed 11 Aug 2020.</Citation></Reference><Reference><Citation>Mendel A, Bernatsky S, Thorne JC, Lacaille D, Johnson SR, Vinet É. Hydroxychloroquine shortages during the COVID-19 pandemic. Ann Rheum Dis. 2020. https://doi.org/10.1136/annrheumdis-2020-217835 .</Citation></Reference><Reference><Citation>Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral infections: an old drug against today’s diseases. Lancet Infect Dis. 2003;3(11):722–7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(03)00806-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269–71.</Citation></Reference><Reference><Citation>Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005;2(1):69.</Citation></Reference><Reference><Citation>Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;56(1):105949. https://doi.org/10.1016/j.ijantimicag.2020.105949 .</Citation></Reference><Reference><Citation>Kim AHJ, Sparks JA, Liew JW, Putman MS, Berenbaum F, Duarte-García A, et al. A rush to judgment? Rapid reporting and dissemination of results and its consequences regarding the use of hydroxychloroquine for COVID-19. Ann Intern Med. 2020;172:819–21.</Citation></Reference><Reference><Citation>Geleris J, Sun Y, Platt J, Zucker J, Baldwin M, Hripcsak G, et al. Observational study of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med. 2020;382(25):2411–8.</Citation></Reference><Reference><Citation>Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ. 2020;369:m1849.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m1849</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahévas M, Tran VT, Roumier M, Chabrol A, Paule R, Guillaud C, et al. Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data. BMJ. 2020;369:m1844.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m1844</ArticleId></ArticleIdList></Reference><Reference><Citation>Borba MGS, Val FFA, Sampaio VS, Alexandre MAA, Melo GC, Brito M, et al. Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial. JAMA Netw Open. 2020;3(4):e208857.</Citation></Reference><Reference><Citation>Cavalcanti AB, Zampieri FG, Rosa RG, Azevedo LCP, Veiga VC, Avezum A, et al. Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19. N Engl J Med. 2020;383:2041–52.</Citation></Reference><Reference><Citation>Boulware DR, Pullen MF, Bangdiwala AS, Pastick KA, Lofgren SM, Okafor EC, et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. N Engl J Med. 2020;383:517–25.</Citation></Reference><Reference><Citation>Skipper CP, Pastick KA, Engen NW, Bangdiwala AS, Abassi M, Lofgren SM, et al. Hydroxychloroquine in nonhospitalized adults with early COVID-19: a randomized trial. Ann Intern Med. 2020;0(0):null.</Citation></Reference><Reference><Citation>McInnes IB. COVID-19 and rheumatology: first steps towards a different future? Ann Rheum Dis. 2020;79(5):551–2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-217494</ArticleId></ArticleIdList></Reference><Reference><Citation>RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, et al. Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report. N Engl J Med. 2020. https://doi.org/10.1056/NEJMoa2021436 .</Citation></Reference><Reference><Citation>Ramiro S, Mostard RLM, Magro-Checa C, van Dongen CMP, Dormans T, Buijs J, et al. Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study. Ann Rheum Dis. 2020;79(9):1143–51. https://doi.org/10.1136/annrheumdis-2020-218479 .</Citation></Reference><Reference><Citation>Aziz M, Fatima R, Assaly R. Elevated interleukin-6 and severe COVID-19: a meta-analysis. J Med Virol. 2020;92:2283–5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.25948</ArticleId></ArticleIdList></Reference><Reference><Citation>Cavalli G, De Luca G, Campochiaro C, Della-Torre E, Ripa M, Canetti D, et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol. 2020;2(6):e325–e31.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(20)30127-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Rojas-Marte GR, Khalid M, Mukhtar O, Hashmi AT, Waheed MA, Ehrlich S, et al. Outcomes in patients with severe COVID-19 disease treated with tocilizumab - a case- controlled study. QJM. 2020;113:546–50.</Citation></Reference><Reference><Citation>Somers EC, Eschenauer GA, Troost JP, Golob JL, Gandhi TN, Wang L, et al. Tocilizumab for treatment of mechanically ventilated patients with COVID-19. Clin Infect Dis. 2020:ciaa954. https://doi.org/10.1093/cid/ciaa954 .</Citation></Reference><Reference><Citation>Furlow B. COVACTA trial raises questions about tocilizumab’s benefit in COVID-19. Lancet Rheumatol. 2020;2(10):e592.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(20)30313-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Spinelli FR, Conti F, Gadina M. HiJAKing SARS-CoV-2? The potential role of JAK inhibitors in the management of COVID-19. Sci Immunol. 2020;5(47):eabc5367. https://doi.org/10.1126/sciimmunol.abc5367 .</Citation></Reference><Reference><Citation>Cantini F, Niccoli L, Matarrese D, Nicastri E, Stobbione P, Goletti D. Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact. J Infect. 2020;81(2):318–56. https://doi.org/10.1016/j.jinf.2020.04.017 .</Citation></Reference><Reference><Citation>National Institutes of Health. COVID-19 Treatment Guidelines. 2020 [cited 2020 29 July]; Available from: https://www.covid19treatmentguidelines.nih.gov/antiviral-therapy/remdesivir/ . Accessed 4 Aug 2020.</Citation></Reference><Reference><Citation>Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of Covid-19 - final report. N Engl J Med. 2020;383:1813–26.</Citation></Reference><Reference><Citation>Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395(10236):1569–78.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)31022-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldman JD, Lye DCB, Hui DS, Marks KM, Bruno R, Montejano R, et al. Remdesivir for 5 or 10 days in patients with severe Covid-19. N Engl J Med. 2020;383:1827–37.</Citation></Reference><Reference><Citation>•• Pan H, Peto R, Abdool Karim Q, Alejandria M, Henao Restrepo AM, Hernandez Garcia C, et al. Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results. medRxiv. 2020:2020.10.15.20209817. Pan et al. report on data from the SOLIDARITY trial which showed no benefit of 4 antiviral agents, including Remdesivir, in treatment of COVID-19.</Citation></Reference><Reference><Citation>Gupta L, Misra DP, Agarwal V, Balan S, Agarwal V. Management of rheumatic diseases in the time of covid-19 pandemic: perspectives of rheumatology practitioners from India. Ann Rheum Dis. 2020a:annrheumdis-2020-217509. https://doi.org/10.1136/annrheumdis-2020-217509 .</Citation></Reference><Reference><Citation>Gupta L, Misra DP, Agarwal V, Balan S, Agarwal V. Response to: 'Telerheumatology in COVID-19 era: a study from a psoriatic arthritis cohort' by Costa et al. Ann Rheum Dis. 2020b:annrheumdis-2020-217953. https://doi.org/10.1136/annrheumdis-2020-217953 .</Citation></Reference><Reference><Citation>Costa L, Tasso M, Scotti N, Mostacciuolo E, Girolimetto N, Foglia F, et al. Telerheumatology in COVID-19 era: a study from a psoriatic arthritis cohort. Ann Rheum Dis. 2020:annrheumdis-2020-217806. https://doi.org/10.1136/annrheumdis-2020-217806 .</Citation></Reference><Reference><Citation>López-Medina C, Escudero A, Collantes-Estevez E. COVID-19 pandemic: an opportunity to assess the utility of telemedicine in patients with rheumatic diseases. Ann Rheum Dis. 2020:annrheumdis-2020-218008. https://doi.org/10.1136/annrheumdis-2020-218008 .</Citation></Reference><Reference><Citation>Stoffer MA, Schoels MM, Smolen JS, Aletaha D, Breedveld FC, Burmester G, et al. Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update. Ann Rheum Dis. 2016;75(1):16–22.</Citation></Reference><Reference><Citation>Gossec L, Paternotte S, Aanerud GJ, Balanescu A, Boumpas DT, Carmona L, et al. Finalisation and validation of the rheumatoid arthritis impact of disease score, a patient-derived composite measure of impact of rheumatoid arthritis: a EULAR initiative. Ann Rheum Dis. 2011;70(6):935–42.</Citation></Reference><Reference><Citation>Salaffi F, Di Carlo M, Vojinovic J, Tincani A, Sulli A, Soldano S, et al. Validity of the rheumatoid arthritis impact of disease (RAID) score and definition of cut-off points for disease activity states in a population-based European cohort of patients with rheumatoid arthritis. Joint Bone Spine. 2018;85(3):317–22.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbspin.2017.05.020</ArticleId></ArticleIdList></Reference><Reference><Citation>Dougados M, Brault Y, Logeart I, van der Heijde D, Gossec L, Kvien T. Defining cut-off values for disease activity states and improvement scores for patient-reported outcomes: the example of the Rheumatoid Arthritis Impact of Disease (RAID). Arthritis Res Ther. 2012;14(3):R129.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/ar3859</ArticleId></ArticleIdList></Reference><Reference><Citation>Mistry J, Sharif M, Prideaux A, Smith C, Sumbwanyambe M, Sibley M, et al. Use of rheumatoid arthritis impact of disease (RAID) in routine care; identification of DAS28 remission and unmet patient-reported outcomes. Rheumatol Adv Pract. 2020;4(2):rkaa013. https://doi.org/10.1093/rap/rkaa013 .</Citation></Reference><Reference><Citation>Fautrel B, Morel J, Berthelot J-M, Constantin A, De Bandt M, Gaudin P, et al. Validation of FLARE-RA, a self-administered tool to detect recent or current rheumatoid arthritis flare. Arthritis Rheumatol. 2017;69(2):309–19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.39850</ArticleId></ArticleIdList></Reference><Reference><Citation>Myasoedova E, De Thurah A, Erpelding M-L, Schneeberger EE, Maribo T, Citera G, et al. Definition and construct validation of clinically relevant cutoffs on the Flare Assessment in Rheumatoid Arthritis (FLARE-RA) questionnaire. Semin Arthritis Rheum. 2020;50(2):261–5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2019.09.004</ArticleId></ArticleIdList></Reference><Reference><Citation>de Thurah A, Maribo T, Stengaard-Pedersen K. Patient self-assessment of flare in rheumatoid arthritis: criterion and concurrent validity of the Flare instrument. Clin Rheumatol. 2016;35(2):467–71.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-014-2849-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Thurah A, Stengaard-Pedersen K, Axelsen M, Fredberg U, Schougaard LMV, Hjollund NHI, et al. Tele-health followup strategy for tight control of disease activity in rheumatoid arthritis: results of a randomized controlled trial. Arthritis Care Res. 2018;70(3):353–60.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.23280</ArticleId></ArticleIdList></Reference><Reference><Citation>Knudsen LR, Thurah A, Lomborg K. Experiences with telehealth followup in patients with rheumatoid arthritis: a qualitative interview study. Arthritis Care Res. 2018;70(9):1366–72.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.23483</ArticleId></ArticleIdList></Reference><Reference><Citation>Ometto F, Raffeiner B, Bernardi L, Botsios C, Veronese N, Punzi L, et al. Self-reported flares are predictors of radiographic progression in rheumatoid arthritis patients in 28-joint disease activity score remission: a 24-month observational study. Arthritis Res Ther. 2016;18(1):89.</Citation></Reference><Reference><Citation>Barton JL, Criswell LA, Kaiser R, Chen YH, Schillinger D. Systematic review and metaanalysis of patient self-report versus trained assessor joint counts in rheumatoid arthritis. J Rheumatol. 2009;36(12):2635–41.</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.090569</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaudhry SR, Thavaneswaran A, Chandran V, Gladman DD. Physician scores vs patient self-report of joint and skin manifestations in psoriatic arthritis. Rheumatology (Oxford). 2013;52(4):705–11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kes355</ArticleId></ArticleIdList></Reference><Reference><Citation>Yazdany J, Trupin L, Gansky SA, Dall’era M, Yelin EH, Criswell LA, et al. Brief index of lupus damage: a patient-reported measure of damage in systemic lupus erythematosus. Arthritis Care Res. 2011;63(8):1170–7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.20503</ArticleId></ArticleIdList></Reference><Reference><Citation>Drenkard C, Yazdany J, Trupin L, Katz PP, Dunlop-Thomas C, Bao G, et al. Validity of a self-administered version of the brief index of lupus damage in a predominantly African American systemic lupus erythematosus cohort. Arthritis Care Res. 2014;66(6):888–96.</Citation></Reference><Reference><Citation>Katz P, Trupin L, Rush S, Yazdany J. Longitudinal validation of the brief index of lupus damage. Arthritis Care Res. 2014;66(7):1057–62.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.22268</ArticleId></ArticleIdList></Reference><Reference><Citation>Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994;21(12):2286–91.</Citation><ArticleIdList><ArticleId IdType="pubmed">7699630</ArticleId></ArticleIdList></Reference><Reference><Citation>Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol. 1994;21(12):2281–5.</Citation></Reference><Reference><Citation>Doward LC, Spoorenberg A, Cook SA, Whalley D, Helliwell PS, Kay LJ, et al. Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis. Ann Rheum Dis. 2003;62(1):20–6.</Citation></Reference><Reference><Citation>Pincus T, Summey JA, Soraci SA Jr, Wallston KA, Hummon NP. Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. Arthritis Rheumatol. 1983;26(11):1346–53.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780261107</ArticleId></ArticleIdList></Reference></ReferenceList></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000551 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000551 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:33403528
|texte= COVID-19: What Do Rheumatologists Need to Know?
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:33403528" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |